Market Overview:
The global vitamin K antagonists (VKA) market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of cardiovascular diseases (CVDs), rising geriatric population, and technological advancements in the field of VKA therapy. Based on type, the global vitamin K antagonists (VKA) market is segmented into oral vitamin K antagonists and injection vitamin K antagonists. Oral vitamin K antagonists are further classified into warfarin and acenocoumarol. Injection vitamin K antagonists are further classified into phenprocoumon and fluindione. Warfarin is the most commonly used oral VKA drug, while phenprocoumon is the most commonly used injectable VKA drug. Based on application, the global Vitamin k antagonist (VKA) market is segmented into venous thromboembolism (VTE), acute coronary syndrome/myocardial infarction (ACS/MI), atrial fibrillation (AF), and others.
 Industry Outlook.svg)
Product Definition:
A vitamin K antagonist is a drug that inhibits the function of vitamin K. These drugs are used to prevent blood clots, and include warfarin, acenocoumarol, and phenprocoumon.
Oral Vitamin K Antagonists:
Oral vitamin K antagonists are used to treat bleeding gums and other oral mucositis. They work by blocking the action of coagulation factor in the blood. Vitamin K antagonists are also used for treating patients with coumarin-related liver disease, warfarin therapy, and hemophilia A & B. The drug is not recommended for use in children younger than 6 years as it may lead to severe hypoglycemia.
Injection Vitamin K Antagonists:
Injection vitamin K antagonists are used in the treatment of warfarin induced bleeding. It works by decreasing the ability of blood clotting factors II, VII, and X to interact with each other. The drug is also known as anticoagulant rodenticide and was first synthesized in 1948. However, it failed to gain approval from U.
Application Insights:
The others segment dominated the global vitamin K antagonist market in 2017 and is expected to witness significant growth over the forecast period. This can be attributed to increasing awareness about nutritional deficiency among general population coupled with rising incidences of chronic diseases, especially cancer. As per WHO, nearly 50% of adults globally are estimated to suffer from micronutrient deficiency.
Vitamin K antagonists are used for treating conditions related to blood clotting such as venous thromboembolism (VTE) and atrial fibrillation/flutter (AF/AFL).
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the high prevalence of VTE, which is a major cause of morbidity and mortality in this region. For instance, as per American Venous Forum, Inc., venous disorders are the second most common cause for disability among adults aged 20-59 years in North America. The incidence rate of VTE is also increasing with age and it affects approximately 1 out of 3 pregnant women during their lifetime putting them at risk for premature birth or fetal death due to hemorrhage or hydrostatic shock.
Asia Pacific is expected to grow at a lucrative rate over the forecast period owing to various initiatives taken by governments across countries such as Japan, China & India aimed towards reducing cardiovascular diseases (CVDs).
Growth Factors:
- Increasing incidence of chronic diseases such as cancer, cardiovascular diseases (CVDs), and diabetes mellitus which leads to the increased demand for VKA drugs.
- The growing geriatric population is also a major growth driver for the global VKA market, as this population is more susceptible to developing chronic diseases that require treatment with VKA drugs.
- The increasing use of VKAs in surgical procedures owing to their clotting-inhibitory properties is another key growth driver for this market.
- Rising awareness about the benefits of using VKAs over other anticoagulants is also propelling the growth of this market worldwide.
Scope Of The Report
Report Attributes
Report Details
Report Title
Vitamin K Antagonists (VKA) Market Research Report
By Type
Oral Vitamin K Antagonists, Injection Vitamin K Antagonists
By Application
VTE, ACS/MI, AF, Others
By Companies
Sanofi, Bristol-Myers Squibb, Bayer, Johnson & Johnson, Genentech (Roche), Boehringer Ingelheim, Lilly, Daiichi Sankyo, Otsuka, AstraZeneca, Sanofi, Aspen, The Medicines Company
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
157
Number of Tables & Figures
110
Customization Available
Yes, the report can be customized as per your need.
Global Vitamin K Antagonists (VKA) Market Report Segments:
The global Vitamin K Antagonists (VKA) market is segmented on the basis of:
Types
Oral Vitamin K Antagonists, Injection Vitamin K Antagonists
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
VTE, ACS/MI, AF, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi
- Bristol-Myers Squibb
- Bayer
- Johnson & Johnson
- Genentech (Roche)
- Boehringer Ingelheim
- Lilly
- Daiichi Sankyo
- Otsuka
- AstraZeneca
- Sanofi
- Aspen
- The Medicines Company
 Market Overview.svg)
Highlights of The Vitamin K Antagonists (VKA) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral Vitamin K Antagonists
- Injection Vitamin K Antagonists
- By Application:
- VTE
- ACS/MI
- AF
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Vitamin K Antagonists (VKA) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Vitamin K antagonists (VKA) are medications that block the action of vitamin K. This can prevent blood clotting and reduce the risk of bleeding. VKA are used to treat a variety of conditions, including: -Haemorrhagic stroke -Thrombocytopenia purpura (a rare disorder that causes low platelet counts)
Some of the major players in the vitamin k antagonists (vka) market are Sanofi, Bristol-Myers Squibb, Bayer, Johnson & Johnson, Genentech (Roche), Boehringer Ingelheim, Lilly, Daiichi Sankyo, Otsuka, AstraZeneca, Sanofi, Aspen, The Medicines Company.
The vitamin k antagonists (vka) market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Vitamin K Antagonists (VKA) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Vitamin K Antagonists (VKA) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Vitamin K Antagonists (VKA) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Vitamin K Antagonists (VKA) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Vitamin K Antagonists (VKA) Market Size & Forecast, 2020-2028
4.5.1 Vitamin K Antagonists (VKA) Market Size and Y-o-Y Growth
4.5.2 Vitamin K Antagonists (VKA) Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Oral Vitamin K Antagonists
5.2.2 Injection Vitamin K Antagonists
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 VTE
6.2.2 ACS/MI
6.2.3 AF
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Vitamin K Antagonists (VKA) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Vitamin K Antagonists (VKA) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Oral Vitamin K Antagonists
9.6.2 Injection Vitamin K Antagonists
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 VTE
9.10.2 ACS/MI
9.10.3 AF
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Oral Vitamin K Antagonists
10.6.2 Injection Vitamin K Antagonists
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 VTE
10.10.2 ACS/MI
10.10.3 AF
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Oral Vitamin K Antagonists
11.6.2 Injection Vitamin K Antagonists
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 VTE
11.10.2 ACS/MI
11.10.3 AF
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Oral Vitamin K Antagonists
12.6.2 Injection Vitamin K Antagonists
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 VTE
12.10.2 ACS/MI
12.10.3 AF
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Oral Vitamin K Antagonists
13.6.2 Injection Vitamin K Antagonists
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 VTE
13.10.2 ACS/MI
13.10.3 AF
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Vitamin K Antagonists (VKA) Market: Competitive Dashboard
14.2 Global Vitamin K Antagonists (VKA) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Sanofi
14.3.2 Bristol-Myers Squibb
14.3.3 Bayer
14.3.4 Johnson & Johnson
14.3.5 Genentech (Roche)
14.3.6 Boehringer Ingelheim
14.3.7 Lilly
14.3.8 Daiichi Sankyo
14.3.9 Otsuka
14.3.10 AstraZeneca
14.3.11 Sanofi
14.3.12 Aspen
14.3.13 The Medicines Company
